{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:49:16Z","timestamp":1753922956945,"version":"3.37.3"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.humpath.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:16:47Z","timestamp":1712762207000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2506-5703","authenticated-orcid":false,"given":"Kamaljeet","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Scalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Legare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Ruhul","family":"Quddus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C James","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.humpath.2024.04.004_bib1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s11912-022-01340-x","article-title":"Germline genetic testing in breast cancer: systemic therapy implications","volume":"24","author":"Bhardwaj","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.humpath.2024.04.004_bib2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.humpath.2024.04.004_bib3","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1245\/s10434-019-07341-8","article-title":"Germline genetic testing: what the breast surgeon needs to know","volume":"26","author":"Plichta","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.humpath.2024.04.004_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.humpath.2017.06.018","article-title":"Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and\/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2","volume":"70","author":"Schoolmeester","year":"2017","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.humpath.2024.04.004_bib5","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/PAS.0b013e3182320cff","article-title":"Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply?","volume":"35","author":"D'Arcy","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2024.04.004_bib6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10549-011-1635-7","article-title":"Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer","volume":"132","author":"Domagala","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.humpath.2024.04.004_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/jnci\/djad063","article-title":"Microsatellite instability in non-colorectal and non-endometrial malignancies in patients with Lynch syndrome","volume":"115","author":"Elze","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.humpath.2024.04.004_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ijc.20638","article-title":"Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients","volume":"113","author":"Kilpivaara","year":"2005","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.humpath.2024.04.004_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10689-017-9990-0","article-title":"A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families","volume":"16","author":"Llovet","year":"2017","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.humpath.2024.04.004_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz027","article-title":"The landscape of somatic genetic alterations in breast cancers from CHEK2 germline mutation carriers","volume":"3","author":"Mandelker","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12885-020-6573-5","article-title":"Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients","volume":"20","author":"Manoharan","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12920-022-01189-w","article-title":"Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation","volume":"15","author":"Sassi","year":"2022","journal-title":"BMC Med Genom"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.31557\/APJCP.2019.20.1.269","article-title":"PTEN genetic and epigenetic alterations define distinct subgroups in North Indian breast cancer patients","volume":"20","author":"Kazim","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"10.1016\/j.humpath.2024.04.004_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13402-012-0071-y","article-title":"p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast","volume":"35","author":"Ercan","year":"2012","journal-title":"Cell Oncol"},{"issue":"4","key":"10.1016\/j.humpath.2024.04.004_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041461","article-title":"PTEN expression as a complementary biomarker for mismatch repair testing in breast cancer","volume":"21","author":"Lopez","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"52","key":"10.1016\/j.humpath.2024.04.004_bib16","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1038\/sj.onc.1207928","article-title":"Alternative splicing and mutation status of CHEK2 in stage III breast cancer","volume":"23","author":"Staalesen","year":"2004","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.humpath.2024.04.004_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pathol.2020.03.001","article-title":"High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer","volume":"52","author":"Eichenauer","year":"2020","journal-title":"Pathology"},{"issue":"11","key":"10.1016\/j.humpath.2024.04.004_bib18","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.neo.2014.09.009","article-title":"Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts","volume":"16","author":"Abdel-Fatah","year":"2014","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.humpath.2024.04.004_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2014.03.557","article-title":"Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer","volume":"133","author":"Alkema","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"52","key":"10.1016\/j.humpath.2024.04.004_bib20","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1038\/sj.onc.1207878","article-title":"Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer","volume":"23","author":"Bartkova","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000351072","article-title":"DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value","volume":"81","author":"Lee","year":"2014","journal-title":"Pathobiology"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ijc.10272","article-title":"Increased expression of CHK2 in human gastric carcinomas harboring p53 mutations","volume":"99","author":"Shigeishi","year":"2002","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.humpath.2024.04.004_bib23","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/sj.bjc.6604037","article-title":"The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus","volume":"97","author":"Sarbia","year":"2007","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.humpath.2024.04.004_bib24","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1182\/blood-2002-04-1078","article-title":"CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas","volume":"100","author":"Tort","year":"2002","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.humpath.2024.04.004_bib25","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1158\/1078-0432.CCR-06-1770","article-title":"Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers","volume":"12","author":"Williams","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.humpath.2024.04.004_bib26","first-page":"3536","article-title":"Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas","volume":"6","author":"Angele","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/annonc\/mdt421","article-title":"ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas","volume":"25","author":"Bueno","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.humpath.2024.04.004_bib28","first-page":"149","article-title":"ATM gene expression is associated with differentiation and angiogenesis in infiltrating breast carcinomas","volume":"21","author":"Cuatrecasas","year":"2006","journal-title":"Histol Histopathol"},{"issue":"2","key":"10.1016\/j.humpath.2024.04.004_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-021-06134-6","article-title":"Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy","volume":"187","author":"Albinsaad","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.humpath.2024.04.004_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4174\/astr.2020.98.6.291","article-title":"Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer","volume":"98","author":"Bae","year":"2020","journal-title":"Ann Surg Treat Res"},{"issue":"2","key":"10.1016\/j.humpath.2024.04.004_bib31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.29271\/jcpsp.2019.02.164","article-title":"Association of p53 overexpression with hormone receptor status and triple negative breast carcinoma","volume":"29","author":"Qamar","year":"2019","journal-title":"J Coll Physicians Surg Pak"},{"issue":"9","key":"10.1016\/j.humpath.2024.04.004_bib32","first-page":"3891","article-title":"Definition of p53 overexpression and its association with the clinicopathological features in luminal\/HER2-negative breast cancer","volume":"33","author":"Kikuchi","year":"2013","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.humpath.2024.04.004_bib33","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/PAS.0000000000000386","article-title":"Combined immunohistochemistry of PLK1, p21, and p53 for predicting TP53 status: an independent prognostic factor of breast cancer","volume":"39","author":"Watanabe","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2024.04.004_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100100","article-title":"p53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance","volume":"36","author":"Mueller","year":"2023","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2024.04.004_bib35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0002-9440(10)65227-3","article-title":"Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast","volume":"155","author":"Perren","year":"1999","journal-title":"Am J Pathol"},{"issue":"31","key":"10.1016\/j.humpath.2024.04.004_bib36","doi-asserted-by":"crossref","first-page":"10816","DOI":"10.1021\/acs.analchem.1c00975","article-title":"Precise quantitation of PTEN by immuno-MRM: a tool to resolve the breast cancer biomarker controversy","volume":"93","author":"Ibrahim","year":"2021","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-021-06463-6","article-title":"PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy","volume":"192","author":"Fan","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.humpath.2024.04.004_bib38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.28021","article-title":"Comprehensive analysis of PTEN status in breast carcinomas","volume":"133","author":"Jones","year":"2013","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.humpath.2024.04.004_bib39","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00432-010-0781-3","article-title":"PTEN mutation spectrum in breast cancers and breast hyperplasia","volume":"136","author":"Yang","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.humpath.2024.04.004_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2626","article-title":"Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations","volume":"12","author":"Banneau","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12885-023-10853-y","article-title":"The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients","volume":"23","author":"Hayama","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2024.04.004_bib42","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1186\/s12885-021-08889-z","article-title":"Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling","volume":"21","author":"Sajjadi","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.humpath.2024.04.004_bib43","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr3405","article-title":"Risk of breast cancer in Lynch syndrome: a systematic review","volume":"15","author":"Win","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.humpath.2024.04.004_bib44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/jmedgenet-2015-103216","article-title":"Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study","volume":"52","author":"Harkness","year":"2015","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.humpath.2024.04.004_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3892\/ol.2021.12485","article-title":"PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma","volume":"21","author":"Ge","year":"2021","journal-title":"Oncol Lett"},{"issue":"5","key":"10.1016\/j.humpath.2024.04.004_bib46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/ng.2931","article-title":"Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type","volume":"46","author":"Witkowski","year":"2014","journal-title":"Nat Genet"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681772400056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681772400056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T21:07:59Z","timestamp":1714684079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681772400056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":46,"alternative-id":["S004681772400056X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.04.004","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}